Immunohistochemistry-quantified EGFR mutant protein expression percentage outperforms next-generation sequencing-derived mutational abundance for predicting tyrosine kinase inhibitor efficacy in non-small cell lung cancer.

Published

Research record: Immunohistochemistry-quantified EGFR mutant protein expression percentage outperforms next-generation sequencing-derived mutational abundance for predicting tyrosine kinase inhibitor efficacy in non-small cell lung cancer.

Published in Oncol Lett; first publication date 2026-11-10. PMID 43054699.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-11-10

Updated

2026-11-21

Disclaimer

professional use